Arab World vs South Korea: Immunization, Hib3 (% of children ages 12-23 months)
Arab World
77.1%
in 2024
South Korea
97.0%
in 2024
Arab World rank
27th
South Korea rank
29th
Immunization, Hib3 (% of children ages 12-23 months) over time
- Arab World
- South Korea
How they compare
South Korea currently reports 97.0% against 77.1% in Arab World, a difference of 19.9%.
That makes South Korea's figure about 1.3 times Arab World's.
Across all 11 years both countries report, South Korea has been ahead every year.
Arab World ranks 27th and South Korea ranks 29th of 43 groups.
South Korea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Arab World | South Korea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 85.3% | 97.5% | 12.2% | South Korea |
| 2020s | 80.9% | 96.6% | 15.7% | South Korea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Arab World or South Korea?
- South Korea, at 97.0% against 77.1% in Arab World as of 2024.
- What is the difference in immunization, hib3 between Arab World and South Korea?
- 19.9%, with South Korea ahead.
- How many years of comparable data are there for Arab World and South Korea?
- 11 years are reported by both, from 2014 to 2024.
- How do Arab World and South Korea rank globally for immunization, hib3?
- Arab World ranks 27th and South Korea ranks 29th of 43 groups.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.